Get the Stockscreener App
12.93
0.15%
0.02
After Hours:
12.92
-0.010
-0.08%
Astria Therapeutics Inc stock is traded at $12.93, with a volume of 1.18M.
It is up +0.15% in the last 24 hours and up +3.03% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$12.91
Open:
$12.98
24h Volume:
1.18M
Relative Volume:
0.62
Market Cap:
$738.11M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-5.343
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
+0.00%
1M Performance:
+3.03%
6M Performance:
+130.89%
1Y Performance:
+31.80%
1-Day Range:
$12.70
$13.08
1-Week Range:
$12.70
$13.16
52-Week Range:
$3.555
$13.29
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
12.93 | 736.97M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
View All
Astria Therapeutics Inc Stock (ATXS) Latest News
Technical Reactions to ATXS Trends in Macro Strategies - news.stocktradersdaily.com
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com UK
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com
Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS - MarketBeat
Affinity Asset Advisors LLC Purchases Shares of 300,000 Astria Therapeutics, Inc. $ATXS - MarketBeat
Will Astria Therapeutics Inc. stock gain from government policies2025 Market Overview & Verified Swing Trading Watchlists - Newser
Astria Therapeutics (NASDAQ:ATXS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Hold" from Analysts - MarketBeat
BioCryst’s Ongoing Boost: Buy or Watch? - StocksToTrade
Astria Therapeutics (NASDAQ:ATXS) Sets New 1-Year HighWhat's Next? - MarketBeat
Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - The Manila Times
BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-TCBX, RNA, ATXS, and FSUN - The Malaysian Reserve
Trading the Move, Not the Narrative: (ATXS) Edition - news.stocktradersdaily.com
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN - Sahm
Astria Therapeutics: Updating Target Price, BioCryst Deal Expected To Go Through, Hold - Seeking Alpha
Why Astria Therapeutics Inc. stock could outperform in 2025Weekly Trade Summary & High Accuracy Buy Signal Tips - moha.gov.vn
Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN - The Malaysian Reserve
Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
(ATXS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Will Astria Therapeutics Inc. stock split again soonJuly 2025 Summary & High Yield Equity Trading Tips - newser.com
How Astria Therapeutics Inc. stock performs in interest rate cycles2025 Retail Activity & Fast Exit Strategy with Risk Control - newser.com
Will Astria Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Review & Weekly High Potential Alerts - newser.com
Can Astria Therapeutics Inc. stock deliver surprise earnings beatWeekly Stock Analysis & Fast Momentum Stock Entry Tips - newser.com
Can Astria Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Return Summary & Detailed Earnings Play Alerts - newser.com
Combining price and volume data for Astria Therapeutics Inc.2025 Support & Resistance & Long-Term Safe Return Strategies - newser.com
Why Astria Therapeutics Inc. is moving todayJuly 2025 Earnings & Reliable Momentum Entry Alerts - newser.com
Is this a good reentry point in Astria Therapeutics Inc.2025 Volatility Report & Weekly Chart Analysis and Guides - newser.com
Will Astria Therapeutics Inc. stock deliver shareholder valueEarnings Risk Report & AI Driven Stock Reports - newser.com
Is Astria Therapeutics Inc. stock a contrarian buyJuly 2025 Technicals & High Conviction Buy Zone Alerts - newser.com
Is Astria Therapeutics Inc. stock overvalued by current metrics2025 Price Action Summary & High Return Trade Guides - newser.com
Astria Therapeutics Inc. (ATXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Astria Therapeutics Inc. stock is in analyst buy zoneQuarterly Trade Report & Breakout Confirmation Alerts - newser.com
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):